Showing results (11-20 of 21) with videos related to
Sort By:
Pageof 3
Journal of Lower Genital Tract Disease|February 25, 2021
Criminal Justice Involvement and Abnormal Cervical Cancer Screening Results Among Women in an Urban Safety Net HospitalDominique Jodry, Danielle Blemur, Minh Ly Nguyen, et al.Brachytherapy|March 29, 2024
Explainable artificial intelligence analysis of brachytherapy boost receipt in cervical cancer during the COVID-19 eraColton Ladbury, Nicholas Eustace, Ari Kassardjian, et al.International Urogynecology Journal|May 2, 2022
Feasibility of combining pelvic reconstruction with gynecologic oncology-related surgeryAdrian Kohut, Taylor Whitaker, Logan Walter, et al.Annals of Surgical Oncology|April 6, 2025
Evaluating the Role of Hyperthermic Intraperitoneal Chemotherapy in Cytoreductive Surgery for Advanced-Stage Ovarian CancerAdrian Kohut, Matthew L Anderson, Vaagn Andikyan, et al.Frontiers in Oncology|November 3, 2022
Niraparib-induced STAT3 inhibition increases its antitumor effectsQianqian Zhao, Adrian Kohut, Yi-Jia Li, et al.Journal of Lower Genital Tract Disease|June 23, 2020
Do High Rates of Atypical Glandular Cells Correlate With Higher Incidence of Disease in a Large Safety Net HospitalTheresa Kuhn, Catherine Finneran, Adrian Kohut, et al.Gynecologic Oncology|December 17, 2019
Evaluating unplanned readmission and prolonged length of stay following minimally invasive surgery for endometrial cancerAdrian Kohut, Mary Cathryn Earnhardt, Nicholas G Cuccolo, et al.Cancers|December 9, 2023
<i>POLD1</i> DEDD Motif Mutation Confers Hypermutation in Endometrial Cancer and Durable Response to PembrolizumabChristina Hsiao Wei, Edward Wenge Wang, Lingzi Ma, et al.Journal for Immunotherapy of Cancer|April 5, 2024
Targeting PARG induces tumor cell growth inhibition and antitumor immune response by reducing phosphorylated STAT3 in ovarian cancerAntons Martincuks, Chunyan Zhang, Theresa Austria, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 24, 2022
Phase I trial of daily subcutaneous SPL-108 injections in combination with paclitaxel in patients with platinum resistant CD44+ advanced ovarian epithelial cancerEugenia Girda, June Hou, David Nelson, et al.Pageof 3